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Background: Urinary tract infections (UTIs) are one of the most common infections treated in ambulatory care
settings, however the epidemiology differs by age and sex. The incidence of UTI is far greater in females than
males, and infection in pediatric patients is more often due to anatomical abnormalities. The purpose of this
research was to describe age- and sex-specific trends in antibiotic susceptibility to common urinary anti-infectives
among urinary isolates of Escherichia coli from ambulatory primary care patients in a regional health maintenance
organization.
Methods: Clinical microbiology data were collected for all urine cultures from patients with visits to primary care
clinics in a regional health maintenance organization between 2005 and 2010. The first positive culture for E. coli
tested for antibiotic susceptibilities per patient per year was included in the analysis dataset. The frequency of
susceptibility to ampicillin, amoxicillin-clavulanate, ciprofloxacin, nitrofurantoin, and trimethoprim/sulfamethoxazole
(TMP/SMX) was calculated for male and female patients. The Cochrane-Mantel-Haenzel test was used to test for
differences in age-stratified susceptibility to each antibiotic between males and females.
Results: A total of 43,493 E. coli isolates from 34,539 unique patients were identified for study inclusion. After
stratifying by age, E. coli susceptibility to ampicillin, amoxicillin-clavulanate, ciprofloxacin, and nitrofurantoin differed
significantly between males and females. However, the magnitude of the differences was less than 10% for all strata
except amoxicillin-clavulanate susceptibility in E. coli isolated from males age 18–64 compared to females of the
same age.
Conclusions: We did not observe clinically meaningful differences in antibiotic susceptibility to common urinary
anti-infectives among E. coli isolated from males versus females. These data suggest that male sex alone should not
be used as an indication for empiric use of second-line broad-spectrum antibiotic agents for the treatment of UTIs.
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Urinary tract infections (UTIs) are one of the most com-
monly treated bacterial infections and account for over
10 million ambulatory care visits annually in the United
States [1]. Antibiotic treatment is typically selected em-
pirically, based on the patient clinical presentation, med-
ical history and local patterns of antibiotic susceptibility
[2]. Because the incidence of UTIs is significantly greater* Correspondence: mcgregoj@ohsu.edu
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reproduction in any medium, provided the oramong women, much of the research has focused on
women. Thus there exists a paucity of research on UTIs
in men. As such, guidelines on the diagnosis, treatment,
and management of UTIs focus largely on infection in
women [2-5].
The incidence, presentation, and course of infection
for UTIs in men and women differ in large part due to
anatomical differences. For the treatment of acute un-
complicated cystitis in women, trimethoprim/sulfameth-
oxazole (TMP/SMX), nitrofurantoin, fosfomycin, and
pivmecillinam are recommended first-line empiric ther-
apies [2,6]. In men, because prostate involvement occursral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics based on first E. coli isolate
from urine specimen in KPNW outpatients 2005-2010a
Characteristic n = 34539









Native American/Alaskan Native 108 (0.3)
Asian 1411 (4.1)
Pacific Islander/Hawaiian 46 (0.1)
Other 767 (2.2)
Unknown 10856 (31.4)
aData are No. (%) unless otherwise indicated.
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lected that achieves therapeutic concentrations in pros-
tatic tissues (e.g., trimethoprim or ciprofloxacin) [7,8].
While historically it was believed that the causative or-
ganism in UTIs differed between men and women, more
recent data has shown that for both sexes the primary
causative pathogen is Escherichia coli, which accounts
for 75-90% of UTIs [8,9]. With the increases in antibiotic
resistance among E. coli and other Enterobacteriaceae
over the past several decades, surveillance data have be-
come critical for appropriate empiric selection of anti-
biotic therapy. U.S. guidelines specify that TMP/SMX
should be avoided for empiric treatment of uncompli-
cated acute cystitis or pyelonephritis in populations
where non-susceptibility to this agent exceeds 20% in
uropathogens [2].
While some surveillance studies have identified signifi-
cant differences in the frequency of susceptibility to
common urinary anti-infectives between isolates col-
lected from male and female patients, this has not been
consistently observed [10,11]. The objective of this study
was to describe age- and sex-specific antibiotic suscepti-
bility patterns for common urinary anti-infectives among
E. coli urine isolates using six years of data from a large
ambulatory primary care patient population.
Methods
Study design and patient population
We conducted a cross-sectional study of urinary E. coli
isolates from outpatients of Kaiser Permanente Northwest
(KPNW) primary care clinics. KPNW is a regional health
maintenance organization that serves over 485,000 mem-
bers in northwest Oregon and southwest Washington. Pri-
mary care clinics were defined as non-specialty care
clinics within the Family Practice, Internal Medicine, or
Pediatrics departments; all primary care clinics were in-
cluded. Urine cultures positive for E. coli that were drawn
from patients with visits in the primary care clinics be-
tween January 1, 2005 and December 31, 2010 were eli-
gible for inclusion in the analysis. Cultures in which less
than 10,000 colonies/mL were identified or 3 or more or-
ganisms were isolated were excluded. The analysis dataset
was then limited to the first isolate tested for antibiotic
susceptibilities per patient and year to minimize potential
bias resulting from repeat culturing [12].
Data collection
Data were electronically extracted from the virtual data
warehouse maintained by the Kaiser Permanente Center
for Health Research. Collected data included patient
demographics, department in which the clinic visit oc-
curred, and all clinical microbiology data for urine cul-
tures. Approval for this study was obtained from the
KPNW institutional review board.Data analysis
The frequency of susceptibility to ampicillin, amoxicillin-
clavulanate, ciprofloxacin, nitrofurantoin, and trimetho-
prim/sulfamethoxazole (TMP/SMX) was calculated for E.
coli isolates stratified by patient sex and year. The
Cochrane-Armitage test for trend was used to identify
changes in the frequency of susceptibility to each anti-
biotic over time independently among males and females.
Patient age at the time of culture was categorized as less
than 18 years, 18–64 years, and 65 years and older. The
frequency of susceptibility to each antibiotic was also
compared across age categories among males and females
using the Cochran-Mantel-Haenszel test. An alpha level
less than or equal to 0.05 was the statistical significance
level for all analyses and data were analyzed with SAS
(version 9.2, SAS Corporation). Clinically significant dif-
ferences were defined as differences of 10% or greater.
Results
Description of study sample
During the study time frame 190,396 urine cultures were
performed at primary care clinic visits; 70,180 were posi-
tive for E. coli and 57,550 of those were tested for anti-
biotic susceptibilities. After restricting the data to the first
isolate per patient per year, 43,493 isolates from 34,539
unique patients remained in the final analysis data set.
Table 1 describes the demographics of these patients. Of
the included isolates, 2,520 (5.8%) were from male patients.
Antibiotic susceptibility of urinary Escherichia coli isolates
by patient sex
Overall, 66.0% (1,664/2,520) of E. coli isolated from
males and 66.3% (27,175/40,971) from females were
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bility was 56.9% (484/850) among males and 67.3% (9,291/
13,798) among females; however, it should be noted that
testing for susceptibility to amoxicillin-clavulanate was
routinely performed and reported only for ampicillin non-
susceptible E. coli. Ciprofloxacin susceptibility for the
E. coli isolates was 93.2% (2,292/2,458) among males
and 95.9% (37,900/39,524) among females, and nitro-
furantoin susceptibility was 96.4% (2,430/2,520) among
males and 97.6% (39,979/40,968) among females. For
TMP/SMX, 86.3% (2,176/2,520) of E. coli isolated from
males were susceptible compared to 84.7% (34,674/
40,958) among females.
Trends in antibiotic susceptibility of urinary Escherichia
coli isolates over time
Figure 1 presents the susceptibility of E. coli to each
antibiotic by sex and year. Susceptibility to amoxicillin-
clavulanate and TMP/SMX decreased significantly over
time among both males and females. Ciprofloxacin sus-
ceptibility also decreased significantly over time among
females, but not males. Table 2 presents the age strati-







































Figure 1 Susceptibility to urinary anti-Infectives by sex and year for E
line, females as red dashed line. a, ampicillin susceptibility (test for trend: m
susceptibility (test for trend: males, p=0.0006; females, p<0.0001); c, ciproflo
d, nitrofurantoin susceptibility (test for trend: males, p=0.4967; females, p=0
males, p=0.0004; females, p<0.0001).males and females. The age-specific susceptibilities dif-
fered significantly between males and females for all an-
tibiotics except TMP/SMX.
Discussion
In this study, we observed statistically significant differ-
ences between males and females in the age-specific sus-
ceptibilities of E. coli to ampicillin, amoxicillin-clavulanate,
ciprofloxacin, and nitrofurantoin. Urinary E. coli isolates
from male patients tended to exhibit increased antibiotic
resistance than isolates from female patients. Despite the
statistical significance of time trends and differences in
age-specific susceptibilities, the magnitude of these differ-
ences was generally less than 5% and thus may not repre-
sent clinically meaningful differences. The exception was
susceptibility to amoxicillin-clavulanate, where susceptibil-
ity was roughly 10% lower in males age 18 to 64 years than
females in the same age group. Yet these differences
should be interpreted cautiously because susceptibility to
amoxicillin-clavulanate was only provided for ampicillin
non-susceptible E. coli isolates in the current analysis. If
all ampicillin susceptible isolates are assumed to be






























. coli cultured from urine. For all figures, males shown as blue solid
ales, p=0.058; females, p=0.6256); b, amoxicillin clavulanate
xacin susceptibility (test for trend: males, p=0.1445; females, p<0.0001);
.5508); e, trimethoprim/sulfamethoxazole susceptibility (test for trend:
Table 2 Susceptibility to urinary anti-infectives by sex and age for E. coli cultured from urine*
Age (years) CMH
<18 18-64 >64 p-value
Ampicillin <0.0001
Male 104 (58.8) 852 (68.5) 708 (64.4)
Female 2564 (62.6) 16988 (65.4) 7623 (69.9)
Amoxicillin clavulanate <0.0001
Male 45 (64.3) 214 (55.6) 225 (57.0)
Female 1113 (73.1) 6040 (67.5) 2138 (64.2)
Ciprofloxacin <0.0001
Male 112 (97.4) 1201 (96.5) 979 (89.1)
Female 2613 (98.4) 25161 (96.9) 10126 (92.8)
Nitrofurantoin <0.0001
Male 174 (98.3) 1214 (97.6) 1042 (94.8)
Female 4023 (98.2) 25413 (97.9) 10543 (96.6)
Trimethoprim/Sulfamethoxazole 0.3888
Male 147 (83.1) 1090 (87.6) 939 (85.4)
Female 3479 (84.9) 21909 (84.4) 9286 (85.1)
*Represents the first isolate for each patient and year.
CMH: Cochrane Maentel Haenszel correlation test.
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than 5% in all age categories (difference not statistically
significant).
While few other studies have explored the differences
in antibiotic susceptibility of uropathogens isolated from
male and female ambulatory patients, our findings are
consistent with the trends observed in the literature. A
recent 10-year study of community UTI in Portuguese
patients also identified differences in antibiotic suscepti-
bility by patient sex. The authors reported that urinary
isolates of E. coli were significantly more resistant to
fluoroquinolones, penicillins, nitrofurantoin, and first
and second generation cephalosporins among men com-
pared to women [13]. Another study focused on pediatric
patients, also identified significantly higher resistance to
TMP/SMX and ciprofloxacin in male versus female pa-
tients [14]. The NAUTICA surveillance study of out-
patient UTIs reported greater antibiotic resistance to
ciprofloxacin, levofloxacin, and TMP/SMX among all
urinary isolates from U.S. and Canadian male patients
[15]. In the CANWARD study, antibiotic susceptibility
among all E. coli isolates (not limited to urine isolates)
collected from Canadian tertiary medical centers were
compared and resistance was also observed to be sig-
nificantly higher to ciprofloxacin, levofloxacin, and
TMP/SMX in isolates collected from male patients ver-
sus female patients [11].
The prevalence and susceptibilities of antibiotic-
resistant bacteria varies widely by geographic region,
thus these data may not be generalizable to all regions.
Local surveillance data of antibiotic susceptibilitieswould be needed to validate these findings in different
patient populations. It should be noted that in our study
resistance to TMP/SMX did not exceed 20%, as it does
in many other regions of the U.S., thus in this patient
setting TMP/SMX may be a viable empiric treatment
option in both males and female patients. Additionally,
antibiotic susceptibilities may differ by other patient or
infection characteristics (e.g., type of UTI). These data
were not available for analysis in this study and further
investigation in this area is needed. Also, because clinical
signs and symptoms of infection were not available and
because not all suspected infections are cultured, the use
of all urinary microbiology from this population cultures
may not represent all true infections.
Currently there exists insufficient data to inform the
development of evidence-based guidelines for the treat-
ment of community UTIs in men. UTIs in adult males
are considered complicated infections according to most
clinical definitions [16-18]. Treatment recommendations
vary from longer durations of therapy to the selection of
broad-spectrum agents such as fluoroquinolones [6].
These recommendations are driven by the high propor-
tion of UTIs in men with prostate involvement and con-
cerns surrounding antibiotic resistance to TMP/SMX
[7,8]. Previous research among Swiss outpatients has
demonstrated the selection of fluoroquinolones versus
TMP/SMX for the treatment of UTI is often influenced
by nonclinical factors [19]. In this study, TMP/SMX, a
recommended first-line agent for UTIs in both children
and adults, the differences in susceptibility between
E. coli isolated from males and females were neither
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are below 20%. Consequently, in this population, there
is no evidence that male sex alone should be an indica-
tion for empiric selection of a second-line broad-
spectrum antibiotic agent for the treatment of UTI.
While more research is needed on treatment effective-
ness of different regimens used to treat community
UTIs in men, population-specific antibiotic susceptibil-
ity data are a necessary component in the empiric anti-
biotic selection process.
Conclusions
In the era of increasing antibiotic resistance, prudent use
of antibiotics is critical to prolong the clinical effective-
ness of existing agents. Excessive use of broad-spectrum
agents, such as fluoroquinolones, increases the evolu-
tionary selective pressures that drive the increasing
prevalence of resistance. These data suggest that first-
line urinary anti-infectives such as TMP/SMX may be
effective agents for treating UTIs in men. While more
data are needed, clinicians should use local surveillance
data to guide the prudent, empiric selection of antibiotic
therapy for UTIs.
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